BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Atreya R, Neurath MF, Siegmund B. Personalizing Treatment in IBD: Hype or Reality in 2020? Can We Predict Response to Anti-TNF? Front Med (Lausanne) 2020;7:517. [PMID: 32984386 DOI: 10.3389/fmed.2020.00517] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
Number Citing Articles
1 Masi L, Capobianco I, Magrì C, Marafini I, Petito V, Scaldaferri F. MicroRNAs as Innovative Biomarkers for Inflammatory Bowel Disease and Prediction of Colorectal Cancer. IJMS 2022;23:7991. [DOI: 10.3390/ijms23147991] [Reference Citation Analysis]
2 Cui G, Florholmen J, Goll R. Could Mucosal TNF Transcript as a Biomarker Candidate Help Optimize Anti-TNF Biological Therapy in Patients With Ulcerative Colitis? Front Immunol 2022;13:881112. [PMID: 35663996 DOI: 10.3389/fimmu.2022.881112] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Atreya R, Neurath MF. IL-23 Blockade in Anti-TNF Refractory IBD: From Mechanisms to Clinical Reality. J Crohns Colitis 2022;16:ii54-63. [PMID: 35553662 DOI: 10.1093/ecco-jcc/jjac007] [Reference Citation Analysis]
4 Atreya R, Bojarski C, Kühl AA, Trajanoski Z, Neurath MF, Siegmund B. Ileal and colonic Crohn'´s disease: Ddoes location makes a difference in therapy efficacy? Current Research in Pharmacology and Drug Discovery 2022. [DOI: 10.1016/j.crphar.2022.100097] [Reference Citation Analysis]
5 Sinclair J, Dillon S, Bottoms L. Perceptions, beliefs and behaviors of nutritional and supplementary practices in inflammatory bowel disease. Sport Sci Health. [DOI: 10.1007/s11332-022-00901-8] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Larsen MD, Nørgård BM, Kjeldsen J. Does Disease Activity After Induction Treatment With Biologics Predict Short-Term Outcome in Crohn's Disease and Ulcerative Colitis? Inflamm Bowel Dis 2022:izab331. [PMID: 34977919 DOI: 10.1093/ibd/izab331] [Reference Citation Analysis]
7 Weidinger C, Krug SM, Voskens C, Moschen AR, Atreya I. Editorial: Loss of Epithelial Barrier Integrity in Inflammatory Diseases: Cellular Mediators and Therapeutic Targets. Front Med (Lausanne) 2021;8:813153. [PMID: 34957170 DOI: 10.3389/fmed.2021.813153] [Reference Citation Analysis]
8 Perez K, Ngollo M, Rabinowitz K, Hamoudi N, Seksik P, Xavier RJ, Daly MJ, Dotan I, Le Bourhis L, Allez M. Meta-Analysis of IBD Gut Samples Gene Expression Identifies Specific Markers of Ileal and Colonic Diseases. Inflamm Bowel Dis 2021:izab311. [PMID: 34928348 DOI: 10.1093/ibd/izab311] [Reference Citation Analysis]
9 Kordulewska NK, Topa J, Rozmus D, Jarmołowska B. Effects of Osthole on Inflammatory Gene Expression and Cytokine Secretion in Histamine-Induced Inflammation in the Caco-2 Cell Line. Int J Mol Sci 2021;22:13634. [PMID: 34948440 DOI: 10.3390/ijms222413634] [Reference Citation Analysis]
10 Khosropanah MH, Vaghasloo MA, Shakibaei M, Mueller AL, Kajbafzadeh AM, Amani L, Haririan I, Azimzadeh A, Hassannejad Z, Zolbin MM. Biomedical applications of silkworm (Bombyx Mori) proteins in regenerative medicine (a narrative review). J Tissue Eng Regen Med 2021. [PMID: 34808032 DOI: 10.1002/term.3267] [Reference Citation Analysis]
11 Gisbert JP, Chaparro M. Primary Failure to an Anti-TNF Agent in Inflammatory Bowel Disease: Switch (to a Second Anti-TNF Agent) or Swap (for Another Mechanism of Action)? J Clin Med 2021;10:5318. [PMID: 34830595 DOI: 10.3390/jcm10225318] [Reference Citation Analysis]
12 Wallace JW, Constant DA, Nice TJ. Interferon Lambda in the Pathogenesis of Inflammatory Bowel Diseases. Front Immunol 2021;12:767505. [PMID: 34712246 DOI: 10.3389/fimmu.2021.767505] [Reference Citation Analysis]
13 Sakaram S, Hasin-Brumshtein Y, Khatri P, He YD, Sweeney TE. A Multi-mRNA Prognostic Signature for Anti-TNFα Therapy Response in Patients with Inflammatory Bowel Disease. Diagnostics (Basel) 2021;11:1902. [PMID: 34679598 DOI: 10.3390/diagnostics11101902] [Reference Citation Analysis]
14 Majidova K, Handfield J, Kafi K, Martin RD, Kubinski R. Role of Digital Health and Artificial Intelligence in Inflammatory Bowel Disease: A Scoping Review. Genes (Basel) 2021;12:1465. [PMID: 34680860 DOI: 10.3390/genes12101465] [Reference Citation Analysis]
15 Giachero F, Jenke A, Zilbauer M. Improving prediction of disease outcome for inflammatory bowel disease: progress through systems medicine. Expert Rev Clin Immunol 2021;17:871-81. [PMID: 34142929 DOI: 10.1080/1744666X.2021.1945442] [Reference Citation Analysis]
16 Mezghiche I, Yahia-Cherbal H, Rogge L, Bianchi E. Novel approaches to develop biomarkers predicting treatment responses to TNF-blockers. Expert Rev Clin Immunol 2021;17:331-54. [PMID: 33622154 DOI: 10.1080/1744666X.2021.1894926] [Reference Citation Analysis]
17 Cui G, Fan Q, Li Z, Goll R, Florholmen J. Evaluation of anti-TNF therapeutic response in patients with inflammatory bowel disease: Current and novel biomarkers. EBioMedicine 2021;66:103329. [PMID: 33862588 DOI: 10.1016/j.ebiom.2021.103329] [Reference Citation Analysis]
18 Schmitt H, Neurath MF, Atreya R. Role of the IL23/IL17 Pathway in Crohn's Disease. Front Immunol 2021;12:622934. [PMID: 33859636 DOI: 10.3389/fimmu.2021.622934] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
19 Schulz-Kuhnt A, Neurath MF, Wirtz S, Atreya I. Innate Lymphoid Cells as Regulators of Epithelial Integrity: Therapeutic Implications for Inflammatory Bowel Diseases. Front Med (Lausanne) 2021;8:656745. [PMID: 33869257 DOI: 10.3389/fmed.2021.656745] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
20 Aldars-García L, Marin AC, Chaparro M, Gisbert JP. The Interplay between Immune System and Microbiota in Inflammatory Bowel Disease: A Narrative Review. Int J Mol Sci 2021;22:3076. [PMID: 33802883 DOI: 10.3390/ijms22063076] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 15.0] [Reference Citation Analysis]
21 Gutiérrez A, Rodríguez-Lago I. How to Optimize Treatment With Ustekinumab in Inflammatory Bowel Disease: Lessons Learned From Clinical Trials and Real-World Data. Front Med (Lausanne) 2021;8:640813. [PMID: 33585530 DOI: 10.3389/fmed.2021.640813] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]